对大脑和头部/部癌症的NRG瘤学试验中的放射治疗计划质量保证:一种AI增强的基于知识的方法
Du Wang1, Huaizhi Geng1, Vinai Gondi2
1Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Cancers
|June 19, 2024
概括
基于知识的规划 (KBP) 模型在临床试验中改善了脑和头癌的放射治疗 (RT) 计划质量. 这种方法提高了协议合规性,目标覆盖率和处于风险的器官节省,证明了多中心RT计划质量保证的有效性.
科学领域:
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
- 临床试验 临床试验
背景情况:
- 放射治疗 (RT) 治疗计划的质量对于临床试验的结果至关重要.
- 基于知识的规划 (KBP) 是RT计划质量保证 (QA) 的一种方法.
研究的目的:
- 在多机构临床试验中使用KBP方法评估针对大脑和头癌的RT计划的质量.
- 评估KBP模型在提高计划质量和减少变化方面的有效性.
主要方法:
- 开发了KBP光子和质子模型,使用来自质母细胞瘤 (GBM) 和鼻癌 (NPC) 试验的高质量图案.
- 应用KBP模型,为试验患者生成新的计划.
- 将KBP生成的计划与提交的协议合规计划,目标覆盖范围和风险器官 (OAR) 剂量的计划进行了比较.
主要成果:
- 与提交的计划相比,KBP生成的RT计划显示出更高的质量.
- KBP强度调节质子疗法 (IMPT) 计划减少了计划质量变化.
- 在多中心临床试验中,KBP工具对RT计划QA有效.
结论:
- 在临床试验中,KBP模型可以显著提高对大脑和头部/部癌症的RT计划质量.
- KBP IMPT为开发改进的质子疗法计划和减少计划质量的变化提供了一个潜在的工具.
- 在多中心环境中,KBP是确保RT计划质量保证的宝贵工具.
更多相关视频
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
2.8K
05:18Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
Published on: October 6, 2023
1.3K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...